{"id":7996,"date":"2026-06-16T09:07:27","date_gmt":"2026-06-16T16:07:27","guid":{"rendered":"https:\/\/highfieldbio.com\/?p=7996"},"modified":"2026-07-16T09:09:29","modified_gmt":"2026-07-16T16:09:29","slug":"highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer","status":"publish","type":"post","link":"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","title":{"rendered":"HighField Biopharmaceuticals\u516c\u53f8\u542f\u52a8K16\u7684II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0cK16\u662f\u4e00\u79cd\u9996\u521b\u7684\u8102\u8d28\u4f53\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u6027\u548c\u8fdb\u5c55\u6027\u8111\u764c\u3002"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

16 6 \u6708, 2026 | HighField Bio Press Release<\/p><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

HighField Biopharmaceuticals\u516c\u53f8\u542f\u52a8K16\u7684II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0cK16\u662f\u4e00\u79cd\u9996\u521b\u7684\u8102\u8d28\u4f53\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u6027\u548c\u8fdb\u5c55\u6027\u8111\u764c\u3002\n<\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

K16 \u662f\u4e00\u79cd\u9488\u5bf9\u9ad3\u7cfb\u7ec6\u80de\u7684\u514d\u75ab\u8c03\u8282\u5242\uff0c\u7531\u5168\u53cd\u5f0f\u7ef4\u7532\u9178 (ATRA) \u7684\u72ec\u7279\u8102\u8d28\u4f53\u7ed3\u6784\u7ec4\u6210\u3002\u00a0<\/strong><\/em><\/p>

2 \u671f\u8bd5\u9a8c\u6b63\u5728\u8bc4\u4f30 K16 \u4e0e\u8d1d\u4f10\u5355\u6297\u8054\u5408\u6cbb\u7597\u590d\u53d1\u6027\u6216\u8fdb\u5c55\u6027\u8111\u764c\u7684\u7597\u6548\u3002<\/strong><\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00a0<\/p>

\u4e2d\u56fd\u676d\u5dde\uff082026\u5e746\u670816\u65e5\uff09<\/strong> \u2013 \u4e13\u6ce8\u4e8e\u5229\u7528\u65b0\u578b\u3001\u66f4\u6709\u6548\u7684\u8102\u8d28\u7597\u6cd5\u6cbb\u7597\u764c\u75c7\u548c\u5176\u4ed6\u75be\u75c5\u7684\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\u9ad8\u7530\u751f\u7269\u5236\u836f\u4eca\u5929\u5ba3\u5e03\uff0c\u5df2\u5728\u4e2d\u56fd\u542f\u52a8K16\u8054\u5408\u8d1d\u4f10\u73e0\u5355\u6297\u6cbb\u7597\u590d\u53d1\u6027\u6216\u8fdb\u5c55\u6027\u80f6\u8d28\u7624\u7684II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>

HighField\u9996\u5e2d\u6267\u884c\u5b98\u5f90\u5b87\u7ea2\u535a\u58eb\u89e3\u91ca\u8bf4\uff0cK16\u7684\u8102\u8d28\u4f53\u5305\u88f9\u7684ATRA\u9776\u5411\u9ad3\u7cfb\u6765\u6e90\u6291\u5236\u7ec6\u80de\uff08MDSC\uff09\uff0c\u8fd9\u4e9b\u7ec6\u80de\u5728\u514d\u75ab\u6291\u5236\u6027\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u53d1\u6325\u7740\u5173\u952e\u4f5c\u7528\u3002K16\u662f\u9996\u4e2a\u80fd\u591f\u8c03\u8282\u9ad3\u7cfb\u7ec6\u80de\u5e76\u4fc3\u8fdbMDSC\u6210\u719f\u5206\u5316\u4e3a\u653b\u51fb\u764c\u7ec6\u80de\u7684\u529f\u80fd\u6027\u514d\u75ab\u7ec6\u80de\u7684\u836f\u7269\u3002<\/p>

\u5f90\u535a\u58eb\u8bf4\uff1a\u201c\u6211\u4eec\u8fdb\u884c\u7684K16\u5355\u836f\u6cbb\u7597\u590d\u53d1\u6027\u80f6\u8d28\u7624\u7684\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u8868\u660e\uff0c\u8be5\u836f\u7597\u6548\u663e\u8457\u3002\u5728\u4e8c\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c\u6211\u4eec\u5c06K16\u4e0e\u8d1d\u4f10\u73e0\u5355\u6297\u8054\u5408\u4f7f\u7528\uff0c\u4ee5\u671f\u9996\u6b21\u5f7b\u5e95\u6839\u9664\u8111\u764c\u3002\u201d<\/p>

\u5728K16\u6cbb\u7597\u80f6\u8d28\u7624\u7684I\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\uff0c17\u4f8b\u60a3\u8005\u7684\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\u8d85\u8fc718\u4e2a\u6708\u3002\u5176\u4e2d1\u4f8b\u60a3\u8005\u8fbe\u5230\u5b8c\u5168\u7f13\u89e3\uff0c\u4e14\u57284\u5e74\u540e\u4ecd\u65e0\u764c\u590d\u53d1\u3002\u901a\u5e38\u60c5\u51b5\u4e0b\uff0c\u5bf9\u4e8e\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\uff08\u80f6\u8d28\u7624\u4e2d\u6700\u5177\u4fb5\u88ad\u6027\u7684\u7c7b\u578b\uff09\u60a3\u8005\uff0c\u4e00\u5e74\u751f\u5b58\u7387\u7ea6\u4e3a251\u81f3401%\u3002<\/p>

\u9664\u4e86\u9488\u5bf9\u80f6\u8d28\u7624\u7684\u5f00\u653e\u6807\u7b7e\u591a\u4e2d\u5fc3 2 \u671f\u8bd5\u9a8c\u4e4b\u5916\uff08NCT07678684<\/a>HighField\u8ba1\u5212\u9488\u5bf9\u5176\u4ed6\u5b9e\u4f53\u7624\u542f\u52a8K16\u7684\u66f4\u591a\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>

\u72ec\u7279\u7684\u8102\u8d28\u6280\u672f
<\/strong>HighField\u7387\u5148\u7814\u53d1\u51fa\u80fd\u591f\u7a7f\u68ad\u4e8e\u590d\u6742\u751f\u7269\u7cfb\u7edf\uff08\u4f8b\u5982\u80bf\u7624\u5fae\u73af\u5883\u548c\u514d\u75ab\u7cfb\u7edf\uff09\u7684\u8102\u8d28\u7ed3\u6784\uff0c\u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u764c\u75c7\u3001\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3001\u4ee3\u8c22\u6027\u75be\u75c5\u53ca\u5176\u4ed6\u75be\u75c5\u7684\u65b0\u578b\u7597\u6cd5\u3002\u5176\u4ea7\u54c1\u662f\u91c7\u7528\u72ec\u7279\u6a21\u5757\u5316\u7cfb\u7edf\u8bbe\u8ba1\u7684\u9ad8\u54c1\u8d28\u8102\u8d28\u7eb3\u7c73\u9897\u7c92\uff0c\u5177\u6709\u826f\u597d\u7684\u751f\u7269\u76f8\u5bb9\u6027\uff0c\u80fd\u591f\u5728\u5faa\u73af\u7cfb\u7edf\u4e2d\u9ad8\u6548\u5b9a\u4f4d\u75c5\u53d8\u7ec4\u7ec7\u3002\u8fd9\u4e9b\u7eb3\u7c73\u9897\u7c92\u7ecf\u8fc7\u4f18\u5316\uff0c\u53ef\u9776\u5411\u591a\u79cd\u75be\u75c5\u673a\u5236\u548c\u7ec6\u80de\uff0c\u5e76\u80fd\u5b89\u5168\u5730\u643a\u5e26\u7279\u5b9a\u5242\u91cf\u7684\u5404\u79cd\u6709\u6548\u8f7d\u8377\uff0c\u4ece\u800c\u6700\u5927\u9650\u5ea6\u5730\u53d1\u6325\u7597\u6548\u3002<\/p>

\u5173\u4e8e HighField \u751f\u7269\u5236\u836f
<\/strong>Highfield\u662f\u4e00\u5bb6\u4e13\u6ce8\u4e8e\u8102\u8d28\u4f53\u6784\u5efa\u4f53\u5728\u514d\u75ab\u80bf\u7624\u5b66\u548c\u57fa\u56e0\u6cbb\u7597\u9886\u57df\u521b\u65b0\u5e94\u7528\u7684\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\u3002Highfield\u7684\u4e3b\u8981\u4ea7\u54c1\u9488\u5bf9\u591a\u79cd\u764c\u75c7\u3002K16\u662f\u4e00\u79cd\u5168\u53cd\u5f0f\u7ef4\u7532\u9178\uff08ATRA\uff09\u4e0e\u8d1d\u4f10\u73e0\u5355\u6297\u8054\u5408\u7684\u8102\u8d28\u4f53\u6784\u5efa\u4f53\u3002K1\u662f\u4e00\u79cd\u836f\u7269\u5305\u88f9\u7684\u514d\u75ab\u8102\u8d28\u4f53\uff0c\u6e90\u81eaHighfield\u7684ADCplex\u3002\u5546\u6807<\/sup> \u5e73\u53f0\u548cHF50\u5747\u6e90\u81ea\u8be5\u516c\u53f8\u7684TCEplex\u3002\u5546\u6807 <\/sup>T\u7ec6\u80de\u8854\u63a5\u5668\u5e73\u53f0\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee https:\/\/highfieldbio.com\/<\/a>.<\/p>

\u5a92\u4f53\u8054\u7cfb\u65b9\u5f0f\uff1a<\/strong>
\u4e39\u00b7\u57c3\u62c9\u7c73\u5b89
Opus \u751f\u7269\u6280\u672f\u901a\u8baf
danieleramian@comcast.net<\/a>
425-306-8716<\/p>

\u4e1a\u52a1\u53d1\u5c55\u8054\u7cfb\u4eba\uff1a<\/strong>
\u6c5f\u94f6
\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u516c\u53f8
Jiangxy@hf-biopharm.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0 The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive […]<\/p>","protected":false},"author":1,"featured_media":7606,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[22],"tags":[],"class_list":["post-7996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"\nHighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0 The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"HighField Biopharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T16:07:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T16:09:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PJWCreative\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\"},\"author\":{\"name\":\"PJWCreative\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\"},\"headline\":\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer\",\"datePublished\":\"2026-06-16T16:07:27+00:00\",\"dateModified\":\"2026-07-16T16:09:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\"},\"wordCount\":461,\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\",\"url\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\",\"name\":\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"datePublished\":\"2026-06-16T16:07:27+00:00\",\"dateModified\":\"2026-07-16T16:09:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/highfieldbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/highfieldbio.com\/#website\",\"url\":\"https:\/\/highfieldbio.com\/\",\"name\":\"HighField Bio\",\"description\":\"Lipid-based Therapeutics Targeting the Tumor Microenvironment\",\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"alternateName\":\"HighField Biopharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/highfieldbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/highfieldbio.com\/#organization\",\"name\":\"HighField Biopharmaceuticals, Inc.\",\"alternateName\":\"HighField Bio\",\"url\":\"https:\/\/highfieldbio.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"width\":1500,\"height\":494,\"caption\":\"HighField Biopharmaceuticals, Inc.\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/highfield-biopharma\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\",\"name\":\"PJWCreative\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"caption\":\"PJWCreative\"},\"sameAs\":[\"https:\/\/highfieldbio.com\"],\"url\":\"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighField Biopharmaceuticals\u542f\u52a8K16\u7684II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0cK16\u662f\u4e00\u79cd\u9996\u521b\u7684\u8102\u8d28\u4f53\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u6027\u548c\u8fdb\u5c55\u6027\u8111\u764c - HighField Biopharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","og_locale":"zh_CN","og_type":"article","og_title":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer - HighField Biopharmaceuticals","og_description":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer K16 is a myeloid cell directed immune modulator composed of a unique liposome construct of all trans retinoic acid (ATRA).\u00a0 The Phase 2 trial is evaluating K16 in combination with bevacizumab for treatment of recurrent or progressive […]","og_url":"https:\/\/highfieldbio.com\/zh\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","og_site_name":"HighField Biopharmaceuticals","article_published_time":"2026-06-16T16:07:27+00:00","article_modified_time":"2026-07-16T16:09:29+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","type":"image\/jpeg"}],"author":"PJWCreative","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#article","isPartOf":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/"},"author":{"name":"PJWCreative","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0"},"headline":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer","datePublished":"2026-06-16T16:07:27+00:00","dateModified":"2026-07-16T16:09:29+00:00","mainEntityOfPage":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/"},"wordCount":461,"publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"image":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","articleSection":["Press Release"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","url":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/","name":"HighField Biopharmaceuticals\u542f\u52a8K16\u7684II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0cK16\u662f\u4e00\u79cd\u9996\u521b\u7684\u8102\u8d28\u4f53\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u6027\u548c\u8fdb\u5c55\u6027\u8111\u764c - HighField Biopharmaceuticals","isPartOf":{"@id":"https:\/\/highfieldbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage"},"image":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","datePublished":"2026-06-16T16:07:27+00:00","dateModified":"2026-07-16T16:09:29+00:00","breadcrumb":{"@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#primaryimage","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/highfieldbio.com\/2026\/06\/16\/highfield-biopharmaceuticals-launches-phase-2-trial-of-k16-a-first-in-class-lipid-based-drug-for-recurrent-and-progressive-brain-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/highfieldbio.com\/"},{"@type":"ListItem","position":2,"name":"HighField Biopharmaceuticals Launches Phase 2 Trial of K16, a First-in-Class Lipid-Based Drug for Recurrent and Progressive Brain Cancer"}]},{"@type":"WebSite","@id":"https:\/\/highfieldbio.com\/#website","url":"https:\/\/highfieldbio.com\/","name":"\u9ad8\u7530\u751f\u7269","description":"\u9488\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u7684\u8102\u8d28\u7597\u6cd5","publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"alternateName":"HighField Biopharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/highfieldbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/highfieldbio.com\/#organization","name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u6709\u9650\u516c\u53f8","alternateName":"HighField Bio","url":"https:\/\/highfieldbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","width":1500,"height":494,"caption":"HighField Biopharmaceuticals, Inc."},"image":{"@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/highfield-biopharma"]},{"@type":"Person","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0","name":"PJW\u521b\u610f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","caption":"PJWCreative"},"sameAs":["https:\/\/highfieldbio.com"],"url":"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/"}]}},"_links":{"self":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/comments?post=7996"}],"version-history":[{"count":5,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7996\/revisions"}],"predecessor-version":[{"id":8001,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7996\/revisions\/8001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media\/7606"}],"wp:attachment":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media?parent=7996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/categories?post=7996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/tags?post=7996"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}